Stock comparison
IDEXX Laboratories
STERIS
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
STE
STERIS
Market cap
$21.26B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | STE | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 53C | IDXX |
| Benjamin Graham | 80A | 68B | IDXX |
| Philip Fisher | 75B | 58C | IDXX |
| Peter Lynch | 71B | 52C | IDXX |
| Joel Greenblatt | 83C | 35D | IDXX |
| Charlie Munger | 87A | 42D | IDXX |
| Terry Smith | 84A | 48D | IDXX |
Side-by-side metrics
| Metric | IDXX | STE |
|---|---|---|
| Market cap | $44.12B | $21.26B |
| P/E (TTM) | 39.0x | 25.3x |
| EV/EBIT | 31.6x | 17.7x |
| ROIC (TTM) | 40.66% | 8.51% |
| Gross margin | 62.05% | 44.25% |
| Net margin | 24.63% | 13.18% |
| Revenue CAGR 5y | 7.56% | 8.88% |
| EPS CAGR 5y | 10.79% | 33.45% |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 1.22% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 8.51%+79%
- Market cap$44.12Bvs $21.26B+52%
- Net margin24.63%vs 13.18%+46%
- Gross margin62.05%vs 44.25%+29%
STE leads on
- Dividend yield1.22%vs 0.0%+100%
- Debt / Equity0.0xvs 0.7x+98%
- EPS CAGR 5y33.45%vs 10.79%+68%
- EV/EBIT17.7xvs 31.6x+44%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.